Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function ...
Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell therapy candidate met its endpoints. The Phase III HOPE-3 trial ...
Stocktwits on MSN
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside
The firm has initiated a global late-stage confirmatory trial of z-rostudirsen in certain patients with Duchenne muscular dystrophy. ・The newly launched study is designed to serve as the confirmatory ...
Regenxbio shares nosedived 43% over two days late last week, reaching 52-week lows on consecutive days, despite generating ...
Taking advantage of investor interest in its Duchenne muscular dystrophy drug, Capricor Therapeutics secured an upsized US$150m late on Thursday from an overnight stock sale. Following an earlier wall ...
-Arkansas Children’s Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical ...
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.
Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results